Cambrian Bio Raises $23M to Expand Longevity Therapeutics Platform
Cambrian BioPharma, a clinical-stage biotechnology company focused on targeting the biological drivers of aging and age-related disease, has raised $23 million in new funding to advance its growing pipeline of therapeutics designed to extend healthspan—the period of life spent in good health. The financing reflects continued momentum across Cambrian’s platform as longevity science attracts increasing institutional interest.
Since its founding in 2019, Cambrian has raised approximately $160 million, including a $100 million Series C round in 2021, and has continued to scale its portfolio through disciplined capital deployment and program expansion. In 2023, the company launched Amplifier Therapeutics, a new pipeline company created to further accelerate development across its anti-aging programs.
Cambrian operates under a Distributed Development Company (DisCo) model, designed to bridge the gap between academic discovery and commercial drug development. This structure combines the sourcing and capital allocation strengths of a venture firm with the execution depth of a pharmaceutical company, while retaining the agility of a biotech startup. Cambrian’s integrated engine enables the identification of promising science, rigorous diligence, and hands-on drug development across multiple programs in parallel.
Biotech venture capital and private equity experts estimate that Cambrian’s combined portfolio of programs could be worth upwards of $1.5 billion, reflecting both the breadth of its pipeline and the strategic value of its platform-based approach to aging biology.
Channel Point Capital Founding Partner Andrew Musto has been involved with Cambrian since August 2023, drawn to the company’s differentiated operating model and ambition to address aging biology at scale.
